Vertex, Obsidian to Seek New Therapies That Regulate Gene Editing
By Colin Kellaher
Vertex Pharmaceuticals Inc. on Thursday said it entered a
research collaboration and licensing agreement with privately held
Obsidian Therapeutics aimed at finding new therapies that regulate
gene editing for the treatment of serious diseases.
Boston drug maker Vertex said Obsidian will use its cytoDRiVE
technology to develop therapy candidates, while Vertex will have
the exclusive option to license worldwide rights to the candidates,
with responsibility for further development and
Vertex said it will pay Obsidian up to $75 million in upfront
payments and research milestones during the research term,
including an equity investment in Obsidian.
The company said Obsidian is eligible to receive up to $1.3
billion in potential research, development, regulatory, and
commercial milestone payments across up to five potential programs,
along with royalties on sales of any products resulting from the
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
April 22, 2021 08:38 ET (12:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.